Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19

References

• CDC Weekly C, Team NCPERE. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China. China CDC Weekly. 2020;2(8):113–122. doi:10.46234/ccdcw2020.032
   PubMedGoogle Scholar
• World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https://COVID19.who.int/. Accessed January 27, 2021.
   Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708‐1720. doi:10.1056/NEJMoa2002032
   Web of Science ®Google Scholar
• Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391‐398. doi:10.7326/0003-4819-149-6-200809160-00005
   Web of Science ®Google Scholar
• Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955‐1960. doi:10.1001/jama.292.16.1955
   PubMed Web of Science ®Google Scholar
• Rodríguez LA, Ruigómez A, Wallander MA, Johansson S. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology. 2009;20(6):800‐806. doi:10.1097/EDE.0b013e3181b5f27d
   Web of Science ®Google Scholar
• Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310‐319. doi:10.1503/cmaj.092129
   PubMed Web of Science ®Google Scholar
• Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120‐2128. doi:10.1001/jama.2009.722
   PubMed Web of Science ®Google Scholar
• Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35‐48. doi:10.1053/j.gastro.2017.04.047
   Web of Science ®Google Scholar
• Hermos JA, Young MM, Fonda JR, Gagnon DR, Fiore LD, Lawler EV. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis. 2012;54(1):33‐42. doi:10.1093/cid/cir767
   PubMed Web of Science ®Google Scholar
• Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5(3):337‐344. doi:10.1586/ecp.12.20
   Web of Science ®Google Scholar
• Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016;355:i5813. doi:10.1136/bmj.i5813
   PubMedGoogle Scholar
• Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552‐558. doi:10.1136/gutjnl-2013-304738
   PubMed Web of Science ®Google Scholar
• Marker S, Barbateskovic M, Perner A, et al. Prophylactic use of acid suppressants in adult acutely ill hospitalised patients: a systematic review with meta-analysis and trial sequential analysis. Acta Anaesthesiol Scand. 2020;64(6):714–728. doi:10.1111/aas.13568
   PubMed Web of Science ®Google Scholar
• Wang CH, Li CH, Hsieh R, et al. Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies. Expert Opin Drug Saf. 2019;18(3):163‐172. doi:10.1080/14740338.2019.1577820
   Web of Science ®Google Scholar
• PubChem Database. Method of using (H+/K+) ATPase inhibitors as antiviral agents; 1996. Available from: https://pubchem.ncbi.nlm.nih.gov/patent/US5945425. Accessed July 29, 2020.
   Google Scholar
• Li H, Meng L, Liu F, et al. H+/K+-ATPase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(1):99–111. doi:10.1517/13543776.2013.741121
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–1836. doi:10.1001/jama.2020.6019
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. 2020;383(10):994. doi:10.1056/NEJMc2022236
   PubMed Web of Science ®Google Scholar
• Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020;115(10):1707–1715. doi:10.14309/ajg.0000000000000798
   PubMed Web of Science ®Google Scholar
• Aby ES, Rodin H, Debes JD. Proton pump inhibitors and mortality in individuals with COVID-19. Am J Gastroenterol. 2020;115(11):1918. doi:10.14309/ajg.0000000000000992
   PubMed Web of Science ®Google Scholar
• Hadi YB, Naqvi SF, Kupec JT. Risk of COVID-19 in patients taking proton pump inhibitors. Am J Gastroenterol. 2020;115(11):1919–1920. doi:10.14309/ajg.0000000000000949
   PubMed Web of Science ®Google Scholar
• Hajifathalian K, Katz PO. Regarding “increased risk of COVID-19 in patients taking proton pump inhibitors”. Am J Gastroenterol. 2020;115(11):1918–1919. doi:10.14309/ajg.0000000000000920
   PubMed Web of Science ®Google Scholar
• Tarlow B, Gubatan J, Khan MA, Cholankeril G. Are proton pump inhibitors contributing to SARS-COV-2 infection? Am J Gastroenterol. 2020;115(11):1920–1921. doi:10.14309/ajg.0000000000000933
   PubMed Web of Science ®Google Scholar
• Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021;70(1):76–84. doi:10.1136/gutjnl-2020-322248
   PubMed Web of Science ®Google Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574–1581. doi:10.1001/jama.2020.5394
   PubMed Web of Science ®Google Scholar
• Park SE, Park SE, Epidemiology PSE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; coronavirus disease-19). Clin Exp Pediatr. 2020;63(4):119–124. doi:10.3345/cep.2020.00493
   PubMedGoogle Scholar
• Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020
   PubMed Web of Science ®Google Scholar
• Choi S-H, Kim HW, Kang J-M, et al. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr. 2020;63(4):125–132. doi:10.3345/cep.2020.00535
   PubMedGoogle Scholar
• Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71(15):896–897. doi:10.1093/cid/ciaa415
   PubMed Web of Science ®Google Scholar
• Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. doi:10.1158/2159-8290.CD-20-0422
   PubMed Web of Science ®Google Scholar
• Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7(5):e314–6. doi:10.1016/S2352-3018(20)30111-9
   PubMed Web of Science ®Google Scholar
• Luxenburger H, Sturm L, Biever P, et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? J Intern Med. 2020;289(1):10.1111/joim.13121. doi:10.1111/joim.13121
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Prasetya IB, Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. Dig Liver Dis. 2020;52(12):1410–1412. doi:10.1016/j.dld.2020.10.001
   PubMedGoogle Scholar
• Ray A, Sharma S, Sadasivam B. The potential therapeutic role of proton pump inhibitors in COVID-19: hypotheses based on existing evidences. Drug Res (Stuttg). 2020;70(10):484–488. doi:10.1055/a-1236-3041
   PubMed Web of Science ®Google Scholar
• Taştemur Ş, Ataseven H. Is it possible to use proton pump inhibitors in COVID-19 treatment and prophylaxis? Med Hypotheses. 2020;143:110018. doi:10.1016/j.mehy.2020.110018
   PubMed Web of Science ®Google Scholar
• Sasaki T, Nakayama K, Yasuda H, et al. A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD. Ther Adv Respir Dis. 2011;5(2):91–103. doi:10.1177/1753465810392264
   PubMedGoogle Scholar
• Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun. 2006;345(3):1014–1021. doi:10.1016/j.bbrc.2006.04.170
   PubMed Web of Science ®Google Scholar
• Vanfleteren LEGW, Spruit MA, Wouters EFM, Franssen FME. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med. 2016;4(11):911–924. doi:10.1016/S2213-2600(16)00097-7
   PubMed Web of Science ®Google Scholar
• Belouzard S, Millet JK, Licitra BN, et al. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–1033. doi:10.3390/v4061011
   PubMed Web of Science ®Google Scholar
• Mazzon M, Marsh M. Targeting viral entry as a strategy for broadspectrum antivirals. F1000Res. 2019;8:F1000 Faculty Rev–1628. doi:10.12688/f1000research.19694.1
   PubMedGoogle Scholar
• Marshansky V, Futai M. The V-type H+ -ATPase in vesicular trafficking: targeting,regulation and function. Curr Opin Cell Biol. 2008;20(4):415–426. doi:10.1016/j.ceb.2008.03.015
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364‐374. doi:10.1007/s11427-020-1643-8
   Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):33. doi:10.1038/s41392-020-0148-4
   PubMed Web of Science ®Google Scholar